Moderna says FDA delayed RSV vaccine approval to end of May
CNBC -

The FDA has not informed Moderna of any issues related to the vaccine's safety, efficacy or quality that would prevent its approval, the biotech company said.

Related Articles

Latest in News

More from CNBC | Business Biotechnology Biotech and Pharmaceuticals Pharmaceuticals Health care industry Moderna Inc Breaking news FDA Pfizer Inc GSK plc business news cnbc Articles US: News Companies Business News Health & Science source:tagname:CNBC US Source